Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance

Our result supports blood plasma as a promising sample source for the genomic analysis in SCLC patients whose tumor tissues are scarcely available and demonstrates potential clinical utilities of cfDNA-based liquid biopsy for clinical management of this deadly disease.